Waldencast Plc: 2024 Annual Report (Form 20-F) Summary
Business Context and Reporting Period
This filing is the Annual Report on Form 20-F for the fiscal year ended December 31, 2024. Waldencast Plc is a global multi-brand beauty and wellness platform organized as an "Up-C" structure, operating through two primary segments: Obagi Medical (professional skincare) and Milk Makeup (clean prestige makeup). The company is incorporated in Jersey and became a tax resident of the United Kingdom on October 29, 2024. It is classified as an Emerging Growth Company and a Foreign Private Issuer.
Key Financial Metrics (Year Ended Dec 31, 2024)
| Metric | 2024 Value | 2023 Value |
|---|---|---|
| Net Revenue | $273.9 million | $218.1 million |
| Gross Profit | $191.7 million | $141.6 million |
| Gross Margin | 70.0% | 64.9% |
| Operating Loss | $(58.6) million | $(81.9) million |
| Net Loss | $(48.6) million | $(106.0) million |
| Adjusted EBITDA | $40.3 million | $24.4 million |
| Cash and Cash Equivalents | $14.8 million | $21.1 million |
| Total Debt (Principal) | $169.0 million | $161.9 million |
Note: The filing does not provide a specific Q4 2024 standalone revenue figure; the data above reflects the full fiscal year 2024.
Material Changes vs. Prior Period
- Revenue Growth: Net revenue increased 25.5% year-over-year, driven by a $33.7 million increase in direct-to-consumer digital channels, $16.8 million growth in U.S. retail, and $14.0 million in international expansion. This was partially offset by an $8.9 million reduction due to the loss of the former Southeast Asia distributor and decreased related-party revenue from the Obagi China Business.
- Profitability Improvement: The Net Loss improved significantly by 54.1% (from $106.0 million to $48.6 million), primarily due to a $23.6 million non-cash gain from the change in fair value of derivative warrant liabilities and a reduction in non-recurring legal costs associated with the SEC investigation.
- Goodwill Impairment: The company recorded a $5.0 million non-cash impairment charge related to the Obagi Medical reporting unit. The carrying value of this unit now equals its fair value, leaving no margin for further decline without triggering additional impairment.
- Debt Restructuring: In March 2025 (subsequent to the reporting period), the company entered into a new $205 million credit facility ($175M term loan, $30M revolver) to refinance its 2022 Credit Agreement.
Guidance, Outlook, and Risks
Management Commentary & Outlook: Management expects capital and operating expenditures to increase as the company expands its international footprint and distribution channels. The company believes existing cash, operating cash flows, and access to credit facilities are sufficient for current needs. No specific numerical guidance for 2025 revenue or earnings was provided in this text.
Material Risks and Contingencies:
- SEC Investigation & Internal Controls: The company is subject to an ongoing SEC investigation regarding the restatement of historical financial results and has identified material weaknesses in internal control over financial reporting that were not fully remediated as of December 31, 2024. This includes deficiencies in risk assessment, control activities, and monitoring.
- Regulatory Risks (Hydroquinone): Obagi's prescription products containing hydroquinone (HQ) are marketed without FDA premarket approval. The FDA has historically expressed safety concerns regarding HQ, and enforcement action could require the company to cease marketing these products or obtain costly approvals.
- Customer Concentration: Milk Makeup is heavily reliant on Sephora, which accounted for a large majority of its U.S. net revenue in 2024. The loss of this partner would materially impact results.
- Goodwill Sensitivity: The Obagi Medical reporting unit has no remaining fair value cushion following the 2024 impairment. Future declines in revenue or profitability could trigger significant additional impairment charges.
- Nasdaq Compliance: The company is under a one-year "Mandatory Panel Monitor" by Nasdaq following previous filing delays. Failure to timely file future reports could result in delisting.
Key Facts for Investor Verification
- Internal Control Remediation: Verify the specific timeline and progress of remediation efforts for the identified material weaknesses in internal controls, as these remain unremediated as of year-end 2024.
- SEC Investigation Status: Monitor for updates on the outcome of the SEC investigation, including potential fines, penalties, or further restatements.
- Hydroquinone Regulatory Status: Track any new FDA communications or enforcement actions regarding Obagi's prescription HQ products, which represent a significant portion of revenue.
- Debt Covenant Compliance: Confirm compliance with the financial covenants of the new 2025 Credit Agreement, specifically the Total Leverage Ratio and Fixed Charge Coverage Ratio.
- Goodwill Valuation: Assess the sensitivity of the Obagi Medical goodwill valuation to changes in revenue growth rates and discount rates, given the lack of a fair value cushion.